Case Overview

The Parties

The Patents at Issue

Three patents were asserted at trial, collectively covering HIV pre-exposure prophylaxis (PrEP) related pharmaceutical compositions and methods. A fourth patent, U.S. Patent No. 9,044,509, also appears in the case record.

• • U.S. Patent No. 9,579,333 (Application No. 14/679,887) — Claim 13 asserted
• • U.S. Patent No. 9,937,191 (Application No. 15/406,344) — Claim 18 asserted
• • U.S. Patent No. 10,335,423 (Application No. 10/335,423) — Claim 18 asserted

The Verdict & Legal Analysis

Outcome

The final judgment produced a mixed result — a relatively rare but legally instructive outcome in patent litigation. Judgment was entered in favor of the United States confirming that Gilead directly infringed all asserted claims through both Truvada® for PrEP and Descovy® for PrEP.

However, judgment was simultaneously entered in favor of Gilead, holding that all asserted claims are invalid on the grounds of anticipation and obviousness. Additionally, claim 18 of the ‘423 Patent was found invalid for lack of enablement — a three-pronged invalidity ruling of notable breadth.

Verdict Cause Analysis

The core legal dynamic here is the simultaneous finding of infringement and invalidity — a scenario where the defendant essentially wins the war despite losing the infringement battle. Gilead’s defense strategy prioritized attacking patent validity on multiple fronts rather than relying solely on non-infringement, which proved decisive.

The invalidity findings on anticipation suggest Gilead successfully argued that prior art disclosed the claimed PrEP methods before the government’s patent priority dates — a significant blow to the prosecution narrative underlying CDC-originated patents. The obviousness findings further indicate that the claimed inventions were not sufficiently differentiated from the existing scientific literature on antiretroviral prophylaxis.

The enablement invalidity of claim 18 of the ‘423 Patent adds another dimension: the court found that the specification did not enable one skilled in the art to practice the full scope of the claim without undue experimentation — a doctrine increasingly scrutinized post-*Amgen v. Sanofi* (2023).

Legal Significance

This verdict carries significant precedential weight for several reasons:

• • Government patent assertion: Federal agencies asserting biomedical patents in district court face the same validity challenges as private plaintiffs — a reminder that sovereign identity does not insulate patent claims from prior art attacks.
• • Enablement post-*Amgen*: The enablement invalidity finding on a pharmaceutical method claim reflects courts’ heightened scrutiny of broad pharmaceutical claims following the Supreme Court’s 2023 Amgen ruling.
• • Anticipation vs. obviousness: Prevailing on both grounds simultaneously signals exceptionally strong prior art — relevant to any party assessing the prosecution history of continuation patents in this family.

Strategic Takeaways

• • For Patent Holders: Prosecution strategy must rigorously distinguish claimed inventions from the prior art landscape, particularly for continuation applications building on earlier government research disclosures. Public scientific publications predating filing can devastate validity.
• • For Accused Infringers: Gilead’s multi-pronged invalidity strategy — simultaneously targeting anticipation, obviousness, and enablement — demonstrates the value of comprehensive prior art analysis as a primary defense pillar rather than a fallback position.
• • For R&D Teams: When evaluating freedom-to-operate for PrEP-related products, validity challenges to government-held patents remain viable and commercially decisive. FTO analysis should incorporate prior art clearance, not just infringement avoidance.